INOVIO Pharmaceuticals, Inc. — Q3 2022 Form 10-Q
Business context and period: This unaudited quarterly report covers the three and nine months ended September 30, 2022. INOVIO is a clinical-stage biotechnology company developing DNA medicines and delivery devices. It has no approved products and reported no product-sale revenue; reported revenue came from collaborations, grants, and contracts.
Financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $9.2 million | $0.3 million | $10.1 million | $0.9 million |
| Operating expenses | $44.9 million | $60.2 million | $221.8 million | $196.6 million |
| Net loss | $37.8 million | $60.2 million | $225.4 million | $196.7 million |
| Net loss per share, basic and diluted | $0.15 | $0.29 | $0.96 | $0.95 |
- Q3 revenue primarily reflected $9.0 million recognized upon completion of deliverables under the U.S. Department of Defense device procurement contract. No revenue was recognized from Advaccine in the periods shown.
- Q3 research and development expense declined 30% year over year to $33.1 million. Nine-month R&D expense fell 7% to $145.5 million. Nine-month general and administrative expense rose to $76.2 million from $39.7 million, principally reflecting the proposed securities-litigation settlement, legal costs, and former CEO separation costs.
- Cash, cash equivalents, and short-term investments totaled $281.9 million at September 30, 2022, down from $401.3 million at December 31, 2021. Working capital was $255.3 million, versus $382.7 million. Accumulated deficit was $1.4 billion.
- Net cash used in operating activities was $179.9 million for the first nine months, compared with $177.8 million in 2021. Investing activities provided $55.6 million, largely reflecting investment maturities and sales; financing activities provided $75.2 million, primarily from common-stock issuance.
- There is no meaningful product gross margin disclosed because the company has no product sales. The filing does not provide a clear operating-margin measure suited to assessing a commercial business.
- Convertible senior notes had a net carrying amount of $16.3 million at September 30, 2022. The notes bear 6.50% interest and mature March 1, 2024, unless earlier converted, redeemed, or repurchased. Operating lease liabilities totaled $16.1 million.
Material changes, outlook, and risks
- COVID-19 program: On October 27, 2022, after the reporting date, INOVIO announced it had stopped internally funding INO-4800 development as a potential COVID-19 heterologous booster. The filing cites reduced global demand, changing regulatory timelines and requirements, diminished government support, and uncertainty around booster opportunities. Advaccine may continue development in its territories using its own resources; INOVIO also plans to participate in the WHO Solidarity Trial Vaccines and continue preclinical work on a pan-COVID-19 candidate.
- Restructuring: In July 2022, the company reduced its workforce by about 55 employees (18% of full-time staff) and terminated agreements with approximately 86% of contractors. It recorded a $1.6 million third-quarter charge. Management said the measures are intended to reduce expenses and extend the cash runway, while warning that restructuring may cause attrition or disrupt execution.
- Runway and funding: Management stated that cash and short-term investments were sufficient for planned operations for at least 12 months from issuance of the financial statements and projected the restructuring and INO-4800 funding change would extend runway into the first quarter of 2025, excluding future capital raises. The company expects continuing losses and says additional capital will be needed to advance development and commercialization; financing may dilute shareholders or be unavailable on acceptable terms. It reported $174.1 million remaining under its $300 million ATM program at September 30, 2022.
- Litigation: A proposed shareholder class-action settlement totals $44 million: $30 million cash, paid by insurance carriers and held in escrow, and $14 million in company shares. Preliminary approval was granted; final approval was scheduled for December 15, 2022. The company also disclosed stayed shareholder derivative cases and ongoing disputes with VGXI and GeneOne, with no trial dates set for the latter matters.
- Pipeline and execution risks: No DNA medicine candidate is approved. The filing describes clinical, regulatory, manufacturing, funding, partner-dependence, supply-chain, competition, and China-related risks. For VGX-3100, the FDA indicated the proposed biomarker-selected REVEAL 2 study would be exploratory and that the existing Phase 3 trials alone were unlikely to support a marketing application; the company plans to complete the modified REVEAL 2 study and then assess the program.
- Investment-market declines produced a $10.6 million nine-month unrealized loss on available-for-sale equity securities; management attributed losses on debt securities mainly to interest-rate changes rather than credit losses. Management reported disclosure controls were effective at the reasonable-assurance level and no material quarter-over-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Final court approval and settlement implementation, including issuance of the $14 million in shares and confirmation of insurance coverage for the cash component.
- Actual cash burn, spending after the restructuring and INO-4800 decision, and whether the stated runway into Q1 2025 remains achievable.
- Future ATM share sales, dilution, and whether additional capital or partnership funding is required.
- Clinical and regulatory progress for priority programs, especially VGX-3100 and INO-3107, and any updated FDA feedback or trial results.
- Advaccine’s INO-4800 development, funding, and regulatory progress, and any resulting milestones or royalties to INOVIO.
- Resolution and potential financial impact of the VGXI and GeneOne disputes, and the company’s ability to meet manufacturing commitments and supply needs.